Perspective Therapeutics (NYSE:CATX) Given New $16.00 Price Target at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its price target lowered by Royal Bank of Canada from $25.00 to $16.00 in a report published on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

CATX has been the subject of a number of other research reports. Wedbush reiterated an “outperform” rating and set a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Oppenheimer dropped their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $5.00 in a report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $4.12 on Monday. The company has a 50 day moving average of $10.78 and a 200-day moving average of $12.32. Perspective Therapeutics has a 12-month low of $2.28 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, sell-side analysts forecast that Perspective Therapeutics will post -0.87 EPS for the current year.

Insider Activity at Perspective Therapeutics

In related news, CFO Jonathan Robert Hunt acquired 12,829 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was bought at an average cost of $3.82 per share, with a total value of $49,006.78. Following the acquisition, the chief financial officer now owns 48,800 shares of the company’s stock, valued at approximately $186,416. The trade was a 35.66 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Johan M. Spoor bought 14,500 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. This represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 33,595 shares of company stock valued at $126,625. Company insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently added to or reduced their stakes in CATX. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $57,000. US Bancorp DE grew its holdings in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics in the 2nd quarter worth $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the second quarter worth $118,000. Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics in the third quarter worth $137,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.